MA38816A - Sulfamidase modifiée et sa production - Google Patents

Sulfamidase modifiée et sa production

Info

Publication number
MA38816A
MA38816A MA038816A MA38816A MA38816A MA 38816 A MA38816 A MA 38816A MA 038816 A MA038816 A MA 038816A MA 38816 A MA38816 A MA 38816A MA 38816 A MA38816 A MA 38816A
Authority
MA
Morocco
Prior art keywords
sulfamidase
modified
modified sulfamidase
production
mammal
Prior art date
Application number
MA038816A
Other languages
English (en)
Other versions
MA38816B1 (fr
Inventor
Charlotta Berghard
Erik Nordling
Gelius Stefan Svensson
Agneta Tjernberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MA38816A publication Critical patent/MA38816A/fr
Publication of MA38816B1 publication Critical patent/MA38816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une sulfamidase modifiée, une composition comprenant une sulfamidase modifiée, ainsi que des procédés de préparation d'une sulfamidase modifiée et l'utilisation thérapeutique d'une telle sulfamidase. En particulier, la présente invention concerne une sulfamidase modifiée ne comprenant pratiquement pas d'épitopes pour des récepteurs de reconnaissance de glycane, permettant ainsi le transport de ladite sulfamidase à travers la barrière hémato-encéphalique d'un mammifère, ladite sulfamidase ayant une activité catalytique dans le cerveau dudit mammifère.
MA38816A 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production MA38816B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162996 2014-04-01
PCT/EP2015/057256 WO2015150490A1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et son procédé de production
EP15713502.1A EP2970413B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Publications (2)

Publication Number Publication Date
MA38816A true MA38816A (fr) 2016-01-20
MA38816B1 MA38816B1 (fr) 2018-10-31

Family

ID=50389999

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38816A MA38816B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Country Status (31)

Country Link
US (2) US9982243B2 (fr)
EP (2) EP2970413B1 (fr)
JP (1) JP6594896B2 (fr)
KR (1) KR20160138282A (fr)
CN (1) CN106414727A (fr)
AU (1) AU2015239126B2 (fr)
BR (1) BR112016022333A2 (fr)
CA (1) CA2943140A1 (fr)
CL (1) CL2016002469A1 (fr)
CY (1) CY1120697T1 (fr)
DK (1) DK2970413T3 (fr)
ES (1) ES2687262T3 (fr)
HK (1) HK1231510A1 (fr)
HR (1) HRP20181507T1 (fr)
HU (1) HUE039691T2 (fr)
IL (1) IL247978A0 (fr)
LT (1) LT2970413T (fr)
MA (1) MA38816B1 (fr)
MX (1) MX368947B (fr)
PH (1) PH12016501812A1 (fr)
PL (1) PL2970413T3 (fr)
PT (1) PT2970413T (fr)
RS (1) RS57842B1 (fr)
RU (1) RU2708026C2 (fr)
SA (1) SA516371859B1 (fr)
SG (1) SG11201608025QA (fr)
SI (1) SI2970413T1 (fr)
SM (1) SMT201800511T1 (fr)
UA (1) UA120432C2 (fr)
WO (1) WO2015150490A1 (fr)
ZA (1) ZA201606492B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
JP2018535654A (ja) * 2015-10-01 2018-12-06 スウェディッシュ オーファン バイオビトラム アクティエボラーグ （ペーウーベーエル） 修飾リソソームタンパク質とその製造
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
US11708569B2 (en) 2018-08-29 2023-07-25 University Of Copenhagen Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
EP3741867A1 (fr) 2019-05-24 2020-11-25 Swedish Orphan Biovitrum AB (Publ) Dosage d'activité de sulfatase
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP0909277B2 (fr) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
WO2003032913A2 (fr) 2001-10-16 2003-04-24 Symbiontics Inc. Procedes et compositions pour le ciblage de proteines a travers la barriere hemato-encephalique (bhe)
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
WO2008109677A2 (fr) * 2007-03-06 2008-09-12 Saint Louis University Enzyme modifiée et procédé de traitement
PL3219795T3 (pl) * 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
EP2394667A1 (fr) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
US9206401B2 (en) 2010-12-22 2015-12-08 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
WO2014194427A1 (fr) 2013-06-06 2014-12-11 Angiochem Inc. Protéines de fusion iduronate-2-sulfatase ciblées
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione

Also Published As

Publication number Publication date
SI2970413T1 (sl) 2018-10-30
IL247978A0 (en) 2016-11-30
EP2970413A1 (fr) 2016-01-20
PT2970413T (pt) 2018-10-23
EP2970413B1 (fr) 2018-07-04
US20180320152A1 (en) 2018-11-08
CL2016002469A1 (es) 2017-12-15
LT2970413T (lt) 2018-10-10
MX2016012910A (es) 2017-07-14
WO2015150490A1 (fr) 2015-10-08
MA38816B1 (fr) 2018-10-31
JP2017514462A (ja) 2017-06-08
CN106414727A (zh) 2017-02-15
CA2943140A1 (fr) 2015-10-08
RU2016140844A3 (fr) 2018-10-11
HK1231510A1 (zh) 2017-12-22
PH12016501812A1 (en) 2017-07-24
HRP20181507T1 (hr) 2018-11-16
AU2015239126B2 (en) 2019-05-02
EP3401325A1 (fr) 2018-11-14
KR20160138282A (ko) 2016-12-02
SA516371859B1 (ar) 2019-01-17
SG11201608025QA (en) 2016-10-28
MX368947B (es) 2019-10-22
RS57842B1 (sr) 2018-12-31
SMT201800511T1 (it) 2018-11-09
ZA201606492B (en) 2019-02-27
RU2708026C2 (ru) 2019-12-03
US20160230155A1 (en) 2016-08-11
JP6594896B2 (ja) 2019-10-23
DK2970413T3 (en) 2018-10-15
ES2687262T3 (es) 2018-10-24
AU2015239126A1 (en) 2016-10-27
PL2970413T3 (pl) 2018-12-31
HUE039691T2 (hu) 2019-01-28
CY1120697T1 (el) 2019-12-11
RU2016140844A (ru) 2018-05-10
BR112016022333A2 (pt) 2017-08-15
US9982243B2 (en) 2018-05-29
UA120432C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
MA38816B1 (fr) Sulfamidase modifiée et sa production
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MA40576A (fr) Anticorps et immunoconjugués anti-her2
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
MX376663B (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
EP4374924A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
MA40249A (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
MX2018013234A (es) Sintesis de indazoles.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
WO2017066712A3 (fr) Modulateurs de maladie de télomères
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201790432A1 (ru) Зонды для визуализации белка хантингтина